LYRA (Lyra Therapeutics) Total Equity: $-10.72 Mil (As of Dec. 2025)


LYRA Lyra Therapeutics Inc LYRA
29 GF Score
Price $0.54
GF Value $2.53
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Lyra Therapeutics Total Equity?

Lyra Therapeutics LYRA +5.87% 29 Total Equity is $-10.72 Mil as of Dec. 2025. GuruFocus rates LYRA with a GF Score™ of 29/100 and a GF Value™ of $2.53 (Possible Value Trap). The stock has 4 warning signs investors should review.

Lyra Therapeutics's total equity for the quarter that ended in Dec. 2025 was $-10.72 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Lyra Therapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Lyra Therapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lyra Therapeutics Total Equity Chart

Lyra Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 34.32 80.75 89.42 11.59 -10.72

Lyra Therapeutics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.59 3.87 1.62 -4.33 -10.72
LYRA
29GF Score
Lyra Therapeutics Inc LYRA
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lyra Therapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Lyra Therapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=36.108-46.825
=-10.72

Lyra Therapeutics's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=36.108-46.825
=-10.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-10.72 Mil mean?
Lyra Therapeutics (LYRA) has a Total Equity of $-10.72 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Lyra Therapeutics and its competitors.
Is Lyra Therapeutics' Total Equity too high?
Lyra Therapeutics' current Total Equity is $-10.72 Mil. Overall, Lyra Therapeutics has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lyra Therapeutics' Total Equity compare to EVFM and CLSDQ?
Lyra Therapeutics' Total Equity of $-10.72 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Lyra Therapeutics and its competitors. Lyra Therapeutics's current Total Equity is $-10.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyra Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lyra Therapeutics (LYRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.53, compared to a current price of $0.54 — trading 78.7% below its estimated fair value. The current Total Equity is $-10.72 Mil. Lyra Therapeutics' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Lyra Therapeutics (LYRA), the current Total Equity is $-10.72 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lyra Therapeutics (LYRA) Overvalued in 2026?

Based on GuruFocus' analysis, Lyra Therapeutics stock appears to be undervalued. The current stock price of $0.54 is trading 78.7% below its estimated GF Value™ of $2.53. GuruFocus considers Lyra Therapeutics to be Possible Value Trap.

Key valuation signals for LYRA:

  • Total Equity: $-10.72 Mil
  • GF Value™: $2.53 vs. price of $0.54 (78.7% below fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the LYRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lyra Therapeutics Business Description

Address 480 Arsenal Way, Watertown, MA, USA, 02472
Lyra Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of anti-inflammatory therapies for the localized treatment of patients with chronic rhinosinusitis, or CRS. Its products include LYR-210 and LYR-220. The company operates in a single operating segment, which is the business of developing targeted medicines to address ear, nose, and throat, or ENT, diseases.
29GF Score

Get the complete analysis for LYRA

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.54
Price
$2.53
GF Value